Brainstorm Cell Therapeutics Inc.
BCLI
$0.642
-$0.0032-0.50%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.53% | -26.71% | -34.14% | -13.62% | -9.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.98% | -34.40% | -45.46% | -38.25% | -27.11% |
| Operating Income | 26.98% | 34.40% | 45.46% | 38.25% | 27.11% |
| Income Before Tax | 10.18% | 28.63% | 32.39% | 14.45% | 42.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.18% | 28.63% | 32.39% | 14.45% | 42.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.18% | 28.63% | 32.39% | 14.45% | 42.75% |
| EBIT | 26.98% | 34.40% | 45.46% | 38.25% | 27.11% |
| EBITDA | 27.14% | 34.70% | 45.91% | 38.65% | 27.38% |
| EPS Basic | 45.89% | 58.32% | 61.53% | 47.23% | 62.45% |
| Normalized Basic EPS | 45.89% | 58.32% | 61.52% | 47.23% | 62.45% |
| EPS Diluted | 45.89% | 58.32% | 61.74% | 47.50% | 62.59% |
| Normalized Diluted EPS | 45.89% | 58.32% | 61.52% | 47.23% | 62.45% |
| Average Basic Shares Outstanding | 68.16% | 65.62% | 74.91% | 69.82% | 54.97% |
| Average Diluted Shares Outstanding | 68.16% | 65.62% | 74.91% | 69.82% | 54.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |